CN113773297A - Resolution method of droxidopa key intermediate - Google Patents
Resolution method of droxidopa key intermediate Download PDFInfo
- Publication number
- CN113773297A CN113773297A CN202111000810.3A CN202111000810A CN113773297A CN 113773297 A CN113773297 A CN 113773297A CN 202111000810 A CN202111000810 A CN 202111000810A CN 113773297 A CN113773297 A CN 113773297A
- Authority
- CN
- China
- Prior art keywords
- key intermediate
- resolution
- threo
- droxidopa
- key
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001104 droxidopa Drugs 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 16
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 238000002425 crystallisation Methods 0.000 claims abstract description 5
- 230000008025 crystallization Effects 0.000 claims abstract description 5
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 claims abstract 2
- 230000002378 acidificating effect Effects 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000000543 intermediate Substances 0.000 abstract description 44
- 229930013930 alkaloid Natural products 0.000 abstract description 8
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 6
- 238000009776 industrial production Methods 0.000 abstract description 2
- QXWYKJLNLSIPIN-JGVFFNPUSA-N droxidopa Chemical compound OC(=O)[C@@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JGVFFNPUSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 14
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 9
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 6
- 229960002179 ephedrine Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940081310 piperonal Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- -1 demethyl ephedrine Chemical compound 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XDDLXZHBWVFPRG-UHFFFAOYSA-N 3,4-bis(phenylmethoxy)benzaldehyde Chemical compound C=1C=CC=CC=1COC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 XDDLXZHBWVFPRG-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 1
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- KRLWOFRQXDUIKD-UHFFFAOYSA-N methyl 1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC=C2C(=O)N(C(=O)OC)C(=O)C2=C1 KRLWOFRQXDUIKD-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method for splitting droxidopa threo type key intermediates (key intermediate I, key intermediate II and key intermediate III in a first, a second and a third synthetic routes), which is characterized in that non-alkaloid, commercialized and easily available S-diphenyl prolinol with low price is used as a splitting agent, a 10-20 times solvent and 0.6-1.0 molar equivalent of the splitting agent are used for reflux reaction, crystallization is carried out at 25-45 ℃, key intermediates I, II, III/S-diphenyl prolinol double salt is obtained by splitting, and then the double salt is dissociated under an acidic condition to obtain L-threo type-key intermediates I, II and III. The resolution method has the advantages of high resolution yield, high chiral purity of the target product obtained by resolution, easy commercial availability of the resolving agent and suitability for industrial production.
Description
Technical Field
The invention belongs to the technical field of preparation of raw material medicines, and particularly relates to a novel resolution method of a droxidopa key intermediate.
Background
Droxidopa (chemical name: L-threo-3- (3, 4-dihydroxyphenyl) serine) is a synthetic amino acid having the following chemical structural formula:
droxidopa can restore abnormally reduced noradrenaline concentration in brain to normal level, so that various symptoms caused by noradrenaline deficiency, such as dizziness, hypodynamia caused by orthostatic hypotension, gait rigidity of a Parkinson disease patient and the like can be improved.
There are many reports on the synthetic route and preparation method of droxidopa, and the summary shows that the following 3 routes are adopted:
route one, reference US4480109, which is a synthetic route of japanese sumitomo pharmaceutical published compound patents of the original research company. According to the patent route, piperonal is used as an initial raw material, firstly, piperonal and glycine are condensed and recrystallized by using water to obtain threo-3- (3, 4-methylenedioxyphenyl) serine, the intermediate reacts with benzyl chloroformate to carry out amino protection to obtain a key intermediate I shown as the following formula, a required L-threo-product is obtained by splitting, and a target product droxidopa is obtained by removing methylene and amino protection, wherein the specific synthetic route is as follows:
and a second route: reference is made to the synthetic chemistry of 2012,18,124-127, in which 3, 4-dibenzyloxybenzaldehyde is used as a starting material to replace piperonal, and then the starting material is condensed with glycine, and the product is post-treated to obtain threo-3- (3, 4-dibenzyloxy-phenyl) serine, the intermediate is reacted with benzyl chloroformate to perform amino protection to obtain a key intermediate II shown in the following formula, and the key intermediate II is resolved to obtain a desired L-threo-product, and then the protecting group is removed to obtain a target product droxidopa, specifically the synthetic route is as follows:
and a third route: reference WO2013142093, which is an improvement of the original synthesis route, still using piperonal as starting material, first condensing with glycine and then treating to obtain threo-3- (3, 4-methylenedioxyphenyl) serine, then performing amino protection with N-methoxycarbonylphthalimide, resolving to obtain the desired L-threo-product, and then removing the protecting group to obtain the desired droxidopa, the specific synthesis route is as follows:
as described above, the currently adopted main routes are route one, route two and route three, the most critical step in the three routes is the resolution of threo-key intermediates (i.e. key intermediate I, key intermediate II and key intermediate III), the resolution quality not only affects the quality of the final product droxidopa, but also the resolution yield has a significant impact on the cost of the final product droxidopa.
However, in the existing literature, most alkaloids such as quinidine, quinine, strychnine, cinchonidine, cinchonine, ephedrine, demethyl ephedrine, dehydroabietylamine and the like are adopted for the resolution of droxidopa threo-key intermediates, and the alkaloids used most are ephedrine and demethyl ephedrine, but the ephedrine and demethyl ephedrine belong to controlled drugs, are limited in commercial purchase and use, are expensive, and limit industrial large-scale use; few resolving agents of non-alkaloid are reported, but the resolution yield and the chiral purity of the resolved L-threo product far do not reach the quality requirement standard of the bulk drugs.
Disclosure of Invention
The invention aims to provide a resolving agent of droxidopa threo-key intermediate and a resolving process thereof, which have the advantages of good resolving effect, easy commercialization and purchase, low cost and suitability for industrial application, aiming at the defects in the existing resolution technology of droxidopa threo-key intermediates (key intermediate I, key intermediate II and key intermediate III).
In the earlier screening process of the droxidopa threo-type key intermediate resolving agent, a novel non-alkaloid resolving agent suitable for the droxidopa threo-type intermediate is found, the resolving agent is easy to commercialize and purchase, the price is low, the resolving effect of the resolving agent applied to the droxidopa threo-type intermediate resolving agent is obviously better than that of the prior art (see examples 1-12), the resolving yield is 40-45%, the yield and purity of an L-type target product after resolving reach 98-99.7%, and the chiral purity requirement can be met without refining raw material medicines.
The invention provides a resolution method of droxidopa threo-key intermediates (key intermediate I, key intermediate II and key intermediate III), which comprises the following reaction steps:
in the above reaction, the raw material for resolution is threo-key intermediates (key intermediate I, key intermediate II, key intermediate III) in the most 3 synthetic routes reported at present.
In the reaction, the resolving agent is S-diphenyl prolinol, and the molar dosage of the resolving agent is 0.6 to 1 time, preferably 0.6 to 0.7 time of that of the key intermediate I, the key intermediate II or the key intermediate III.
In the above reaction, the solvent for resolution is selected from one or more of protic solvent including ethanol, methanol, isopropanol, n-butanol, n-pentanol and tetrahydrofuran, and is mixed in any proportion; the aprotic solvent comprises one or more of ethyl acetate, toluene, dichloromethane and chloroform which are mixed according to any proportion; the polar solvent includes DMF. Wherein the protic solvent is preferably isopropanol or n-butanol, and the aprotic solvent is preferably ethyl acetate.
In the above reaction, the ratio of the amount (volume) of the solvent to the weight (g) of the starting material to be resolved is selected from 10:1 to 20:1, preferably 10: 1.
In the reaction, the reaction temperature is reflux, the crystallization temperature is different from the selected solvent and ranges from 25 ℃ to 45 ℃,
preferably 30-45 deg.C.
The advantages of the invention are as follows: the invention aims to provide a method for splitting droxidopa threo-type-key intermediates (key intermediate I, key intermediate II and key intermediate III), which overcomes the defects that alkaloid is generally adopted as a splitting agent in the prior art, commercial purchase is not easy, cost is high and industrial amplification is not easy, and compared with the prior art, the splitting agent and the splitting process adopting the technology of the invention have the following advantages:
1. compared with the tube product alkaloid commonly adopted in the prior art as the resolving agent, the resolving agent S-diphenyl prolinol adopted by the invention is a commercial product, is easy to purchase, has lower price and greatly reduced cost compared with the alkaloid, and is more suitable for industrial production;
2. compared with the resolving agent in the prior art, the resolving agent S-diphenyl prolinol has better resolving effect, the resolving yield is 40-45%, the chiral purity of the L-threo-products (L-threo-key intermediate I, L-threo-key intermediate II and L-threo-key intermediate III) after primary resolution is 98-99.5%, and the chiral purity requirement of the raw material medicaments can be met without refining the chiral purity.
Drawings
FIG. 1: example 1 resolution of the resulting L-threo-key intermediate I chiral purity HPLC profile;
FIG. 2: example 2 resolution of the resulting L-threo-key intermediate II chiral purity HPLC profile;
FIG. 3: example 3 the resulting L-threo-key intermediate III chiral purity HPLC profile was resolved.
Detailed Description
In order to make the technical problems, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail with reference to the following embodiments, but the present invention is not limited thereto. Any equivalent substitutions of this area of art made in accordance with the present disclosure are intended to be within the scope of the present invention.
Example 1
Putting 3g (0.0088 mol) of the key intermediate I in the first route into a three-necked bottle, adding 30ml of isopropanol, then adding 1.34g (0.0053 mol) of S-diphenylprolinol, heating and refluxing for 30min-1h, cooling the reaction solution to 35 +/-2 ℃, crystallizing for 3h, performing suction filtration, and washing the filtrate with isopropanol to obtain 2.4g of the key intermediate I-S-diphenylprolinol double salt with the yield of 43%.
Dissolving the double salt in 20ml of ethyl acetate, cooling to 10-15 ℃, dropwise adding dilute hydrochloric acid to adjust the pH of the solution to be =2-3, stirring for 30min, layering, extracting a water layer with EA until no product exists, combining organic layers, washing with saturated saline solution, drying and concentrating to be dry, adding 20ml of methanol to dissolve residues, cooling to 10-15 ℃, dropwise adding 50ml of purified water, stirring and crystallizing for 1.5-2h, performing suction filtration, and performing vacuum drying at 45 ℃ overnight to obtain 1.2g of an L-threo-key intermediate I, wherein the yield is 40%, and the chiral purity: 98.54% (HPLC detection pattern is shown in figure 1).
Example 2
Putting 3g (0.0059 mol) of the key intermediate II in the second route into a three-necked bottle, adding 30ml of isopropanol, then adding 0.89g (0.00354 mol) of S-diphenylprolinol, heating and refluxing for 30min-1h, cooling the reaction solution to 30 +/-2 ℃, crystallizing for 3h, carrying out suction filtration, and washing the filtrate with isopropanol to obtain 2.07g of the key intermediate II-S-diphenylprolinol double salt with the yield of 46%.
Dissolving the double salt in 20ml of ethyl acetate, cooling to 10-15 ℃, dropwise adding diluted hydrochloric acid to adjust the pH of the solution to be =2-3, stirring for 30min, layering, extracting a water layer with EA until no product exists, combining organic layers, washing with saturated saline solution, drying and concentrating to be dry, adding 20ml of methanol to dissolve residues, cooling to 10-15 ℃, dropwise adding 50ml of purified water, stirring and crystallizing for 1.5-2h, performing suction filtration, and performing vacuum drying at 45 ℃ overnight to obtain 1.32g of an L-threo key intermediate II, wherein the yield is 44%, and the chiral purity: 99.35% (HPLC detection spectrum is shown in figure 2).
Example 3
Putting 3g (0.0084 mol) of the key intermediate III in the third route into a three-necked bottle, adding 30ml of isopropanol, then adding 1.28g (0.005 mol) of S-diphenyl prolinol, heating and refluxing for 30min-1h, cooling the reaction liquid to 45 +/-2 ℃, crystallizing for 3h, performing suction filtration, and washing the filtrate with isopropanol to obtain 2.19g of the key intermediate III-S-diphenyl prolinol double salt with the yield of 46%.
Dissolving the double salt in 20ml of ethyl acetate, cooling to 10-15 ℃, dropwise adding diluted hydrochloric acid to adjust the pH of the solution to be =2-3, stirring for 30min, layering, extracting a water layer with EA until no product exists, combining organic layers, washing with saturated saline solution, drying and concentrating to be dry, adding 20ml of methanol to dissolve residues, cooling to 10-15 ℃, dropwise adding 50ml of purified water, stirring and crystallizing for 1.5-2h, performing suction filtration, and performing vacuum drying at 45 ℃ overnight to obtain 1.35g of an L-threo key intermediate III, wherein the yield is 45%, and the chiral purity is as follows: 99.68% (HPLC detection pattern is shown in figure 3).
Examples 4 to 12
The yields and chiral purities of the L-target products obtained by the process described in examples 1 to 3, with variation of the resolution solvent, the amount of resolving agent and the crystallization temperature are summarized in the following table:
note: 1. the amounts of resolving agent in the table refer to: the mole multiple of the resolving agent to the resolving raw material;
2. the solvent amounts in the tables refer to: the ratio of the volume of solvent (ml) used to the weight of the starting material to be resolved (g).
Claims (7)
1. The resolution method of the droxidopa threo type key intermediate I is characterized in that S-diphenyl prolinol is adopted as a resolving agent in an organic solvent, reflux reaction and cooling crystallization are carried out to obtain a key intermediate I double salt, and then the key intermediate I double salt is dissociated under an acidic condition to obtain the L-threo type key intermediate I, wherein the reaction formula is as follows:
2. the resolution method according to claim 1, characterized in that the organic solvent used for resolution is selected from one or more of ethanol, methanol, isopropanol, n-butanol, n-pentanol, tetrahydrofuran, ethyl acetate, toluene, dichloromethane, chloroform and DMF, and is mixed according to any proportion.
3. The resolution solvent according to claim 2, characterized in that one or more of isopropanol, n-butanol, ethyl acetate are preferably mixed in any proportion.
4. The resolution solvent according to claim 2, characterized in that the amount of solvent used is 10-20ml per 1g of key intermediate I.
5. The resolution process according to claim 1, characterized in that the molar amount of the resolving agent is 0.6-1.0 times the molar amount of the key intermediate I.
6. Resolution process according to claim 1, characterized in that the molar amount of resolving agent is preferably 0.6 to 0.7 times the molar amount of key intermediate I.
7. The resolution process according to claim 1, characterized in that the crystallization temperature is 25-45 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111000810.3A CN113773297B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711419972.4A CN109956922B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
| CN202111000810.3A CN113773297B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711419972.4A Division CN109956922B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113773297A true CN113773297A (en) | 2021-12-10 |
| CN113773297B CN113773297B (en) | 2023-12-26 |
Family
ID=67020926
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111000810.3A Active CN113773297B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
| CN202111002402.1A Active CN113816943B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
| CN201711419972.4A Active CN109956922B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111002402.1A Active CN113816943B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
| CN201711419972.4A Active CN109956922B (en) | 2017-12-25 | 2017-12-25 | Resolution method of droxidopa key intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN113773297B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084928A1 (en) * | 1982-01-14 | 1983-08-03 | Sumitomo Chemical Company, Limited | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CN102584795A (en) * | 2012-01-13 | 2012-07-18 | 唐虹 | Preparing method of crizotinib |
| IN2013MU02758A (en) * | 2013-08-23 | 2015-07-03 | Cadila Healthcare Ltd |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5629551A (en) * | 1979-08-20 | 1981-03-24 | Sumitomo Chem Co Ltd | Preparation of optically active threo-3- 3,4- dihydroxyphenyl serine |
| CA1223602A (en) * | 1983-05-25 | 1987-06-30 | Naohito Ohashi | Process for producing 3-(3,4-dihydroxyphenyl) serine |
| JPS6259274A (en) * | 1985-05-29 | 1987-03-14 | Sumitomo Pharmaceut Co Ltd | Production of optically active phenylserine derivative |
| WO2013142093A1 (en) * | 2012-03-20 | 2013-09-26 | Chelsea Therapeutics, Inc. | Method for the synthesis of droxidopa |
| EP3168208A1 (en) * | 2015-11-11 | 2017-05-17 | Quimica Sintetica, S.A. | Processes for the preparation of diastereomerically and enantiomerically enriched oxazolines |
-
2017
- 2017-12-25 CN CN202111000810.3A patent/CN113773297B/en active Active
- 2017-12-25 CN CN202111002402.1A patent/CN113816943B/en active Active
- 2017-12-25 CN CN201711419972.4A patent/CN109956922B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084928A1 (en) * | 1982-01-14 | 1983-08-03 | Sumitomo Chemical Company, Limited | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CN102584795A (en) * | 2012-01-13 | 2012-07-18 | 唐虹 | Preparing method of crizotinib |
| IN2013MU02758A (en) * | 2013-08-23 | 2015-07-03 | Cadila Healthcare Ltd |
Non-Patent Citations (1)
| Title |
|---|
| 唐除痴等: "《不对称反应中的有机磷试剂》", 南开大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109956922A (en) | 2019-07-02 |
| CN113773297B (en) | 2023-12-26 |
| CN109956922B (en) | 2021-12-10 |
| CN113816943A (en) | 2021-12-21 |
| CN113816943B (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011161690A1 (en) | Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof | |
| US20120004463A1 (en) | Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane | |
| CN110668995A (en) | Tofacitinib citrate intermediate and preparation method of tofacitinib citrate | |
| CN110845502A (en) | Preparation method of 7-bromopyrrolo [2,1-f ] [1,2,4] thiazine-4-amine | |
| CN111018862B (en) | Preparation method of ibrutinib | |
| EP3100735B1 (en) | Crystalline fosaprepitant dicyclohexylamine salt and its preparation | |
| CN111233833A (en) | Preparation method of deuterated macrocyclic compound | |
| US10975117B2 (en) | Method for producing lacosamide and intermediate thereof | |
| EP4159719A1 (en) | Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt | |
| CN109956922B (en) | Resolution method of droxidopa key intermediate | |
| US8877941B2 (en) | Process for the resolution of medetomidine and recovery of the unwanted enantiomer | |
| CN102675283B (en) | Method for preparing bepotastine by condensation under acidic condition | |
| JP6947354B2 (en) | How to make linagliptin | |
| CN108409589A (en) | A kind of preparation method of the beta-amino acid esters of band chirality | |
| CN110981934B (en) | Synthetic method of argatroban hydrate | |
| CN110734393B (en) | Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride | |
| CN113121549B (en) | Method for stereoselectively synthesizing chiral lactone, chiral compound and application thereof | |
| CN114341155A (en) | Preparation method of peptide amide compound and intermediate thereof | |
| CN102219729B (en) | Method for preparing optically pure 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)3,5-dipicolinic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethyl methyl ester | |
| KR20110010803A (en) | Process for preparation of enantiomerically pure (s)-1-phenyl-1,2,3,4- tetrahydroisoquinoline | |
| CN103787921A (en) | Method for preparing high-optical-purity trans-1,2-cyclodiamine | |
| IE45148B1 (en) | Optically active 2-(2-phenyl-5-benzoxazolyl)propionic acids | |
| EP3068746B1 (en) | Process for the preparation of enantiomerically pure 1-aminoindan | |
| CN111362852B (en) | Preparation method of medicine intermediate 1-tert-butoxycarbonyl-3-azetidinone | |
| CN111094270B (en) | Optically active pyrrolidine compound and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |